Introduction: Higher levels of inflammatory biomarkers interleukin (IL)-1? IL-6 and tumour necrosis factor (TNF-?) were detected in patients diagnosed with T1DM. Serum TNF-? C-reactive protein also found to be significantly higher T2DM. IL-1 superfamily (IL-1? IL-18 IL-33) has an important function DM-associated pathogenesis through alteration immune responses. Little is known about the role metformin type 2 diabetes mellitus respect serum IL-33 ST-2 receptors thus present study we aiming at exploring such role. Methods: The study included 45 age range 30 less than 60 years. Patients given (500 mg orally Glucomet Furat Pharmaceutical Industries Iraq) for months. level was evaluated using Human Interleukin 33 ELISA Kit (BT lab China) sST2(Soluble ST2) (Elabscience USA). Results: Treatment resulted significant reduction suppression tumorigenicity receptor (ST-2) from 0.71 ±0.157 (µg/ml) 0.59 ±0.11 (p < 0.001) increase interleukin- 33 (IL-33) 0.60 ±0.18 pg/ml 0.75 ±0.13 0.001). Conclusion: revealed a crucial receptors glycemic control since increment associated good suggesting disease response treatment. Key words: mellitus interleukin-33 Give me A graphical abstract (500-pixel height 900-pixel width as JPG or TIFF file) required. This graphic should attractive reader relevant manuscript title. Further it give prompt visual impression necessity no specific results. You can upload figure too.